Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor
XTalks
FEBRUARY 27, 2024
Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.” WuXi Advanced Therapies (WuXi ATU) has already gotten an FDA nod for its Philadelphia site to start the analytical testing and manufacturing of Amtagvi.
Let's personalize your content